Surge in ADHD Stimulant Prescriptions Amid COVID-19 Pandemic

Research indicates a significant increase in prescriptions for stimulant medications used to treat Attention Deficit Hyperactivity Disorder (ADHD) among adults since the onset of the COVID-19 pandemic. A study conducted by the Ontario Drug Policy Research Network revealed that new prescriptions for ADHD stimulants in Ontario, Canada, more than doubled from January 2016 to June 2024, with a notable surge particularly among young adults aged 18 to 24. The study documented that 327,053 adults received at least one new stimulant prescription during this period, with women constituting 55% of this group. This contrasts with pre-pandemic trends, where stimulant prescriptions were more evenly distributed between genders.

Adult ADHD Medication Prescriptions Have Doubled Since the Onset of theDoubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic, shows research at St. Michael’sThe Independent

Experts attribute the rise in ADHD diagnoses and stimulant prescriptions to several factors. Dr. Mina Tadrous, co-author of the study, noted that increased awareness of adult ADHD, particularly among women, and improved access to care through virtual health services have played crucial roles. The pandemic has also led to heightened psychological distress and increased screen time, which may have exacerbated symptoms and awareness of ADHD. Dr. Tara Gomes, another lead researcher, emphasized that while these trends may reflect better recognition and treatment of ADHD, the rapid increase raises concerns about the appropriateness of diagnoses and prescribing practices.

Adult ADHD Medication Prescriptions Have Doubled Since the Onset of theThe IndependentDoubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic, shows research at St. Michael’s

The swift rise in stimulant prescriptions has prompted scrutiny regarding the quality of diagnostic practices. The study found that approximately 25% of new stimulant recipients were also diagnosed with anxiety or depression, raising questions about the off-label use of stimulants for conditions that typically require different treatment approaches. Moreover, the proportion of prescriptions initiated by psychiatrists decreased from 26% to 18% post-pandemic, while those from nurses and nurse practitioners increased from 2% to 10%. This shift suggests a growing reliance on non-specialist providers, which may impact the thoroughness of evaluations.

Adult ADHD Medication Prescriptions Have Doubled Since the Onset of the

Critics, including Dr. Gomes, caution that the rapid increase in stimulant prescriptions, coupled with shorter assessment timelines and non-specialist involvement, could lead to misdiagnoses and inappropriate treatment. The influence of social media on ADHD awareness, particularly among young adults, has also been highlighted as a potential factor contributing to this trend. Experts advocate for rigorous assessment protocols to ensure that treatment decisions align with established clinical standards and to safeguard against potential health risks associated with inappropriate stimulant use.

Doubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic, shows research at St. Michael’s

The increase in ADHD stimulant prescriptions is not limited to Canada; similar trends have been observed in the United States, Australia, the United Kingdom, and Finland. The global nature of this phenomenon underscores the need for ongoing monitoring and evaluation of ADHD treatment practices. As health systems adapt to the evolving landscape of mental health care, balancing the benefits of increased recognition and treatment of adult ADHD with the risks associated with rapid prescribing growth remains a critical challenge.

Adult ADHD Medication Prescriptions Have Doubled Since the Onset of theDoubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic, shows research at St. Michael’s

• “ Tara Gomes from the Ontario Drug Policy Research Network said: “Our findings may reflect improved recognition and treatment of ADHD in adulthood; however, the speed and scale of this growth also raises important questions about how diagnoses are being made, and if this prescribing is always appropriate.” — Dr. Tara Gomes, Ontario Drug Policy Research Network

The Independent